Vive la resistant starch : A potential treatment for metabolic dysfunction-associated steatohepatitis

被引：0

作者：

Zhang, Xiang ^{[1
]}

Yu, Jun ^{[1
]}

Wong, Vincent Wai-Sun ^{[1
,2
]}

机构：

[1] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, Med Data Analyt Ctr, Dept Med & Therapeut, Hong Kong, Peoples R China

来源：

CELL METABOLISM | 2023年 / 35卷 / 09期

关键词：

D O I：

10.1016/j.cmet.2023.07.004

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Metabolic dysfunction-associated steatotic liver disease is a prevalent chronic liver disease that affects nearly a third of the global adult population. Here, we preview a randomized controlled clinical trial on the potential benefits and underlying mechanisms of using resistant starch, a prebiotic, for treating this common liver condition.

引用

页码：1491 / 1493

页数：3

共 50 条

[21] Monocyte bioenergetics: An immunometabolic perspective in metabolic dysfunction-associated steatohepatitis
Sangineto, Moris
Ciarnelli, Martina
Colangelo, Tommaso
Moola, Archana
Bukke, Vidyasagar Naik
Duda, Loren
Villani, Rosanna
Romano, Antonino
Giandomenico, Stefania
Kanwal, Hina
Serviddio, Gaetano
CELL REPORTS MEDICINE, 2024, 5 (05)
[22] Clearance of senescent cells alleviates metabolic dysfunction-associated steatohepatitis
Sayed, Nilofer
Chong, Suet Yen
Ting, Hui Jun
Zhang, Ziyang
Li, Phyllis Gan Xiu
Nagpal, Shakti
Tan, Michelle Siying
Tan, De En
Syn, Nicholas
Muthiah, Mark
Dan, Yock Young
Storm, Gert
Wang, Jiong Wei
JOURNAL OF HEPATOLOGY, 2024, 80 : S565 - S566
[23] Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma
Etzion, Ohad
Bareket-Samish, Avital
Yardeni, David
Fishman, Pnina
BIOMEDICINES, 2024, 12 (04)
[24] Resmetirom: Breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis
Saeed, Anzel
Rai, Kuldeep Dalpat
Saeed, Muzammil
LIVER RESEARCH, 2024, 8 (03) : 193 - 194
[25] Innovative approaches to metabolic dysfunction-associated steatohepatitis diagnosis and stratification
Matboli, Marwa
Hamady, Shaimaa
Saad, Maha
Khaled, Radwa
Khaled, Abdelrahman
Barakat, Eman MF.
Sayed, Sayed Ahmed
Agwa, SaraH. A.
Youssef, Ibrahim
NON-CODING RNA RESEARCH, 2025, 10 : 206 - 222
[26] Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis
Ramos-Molina, Bruno
Rossell, Joana
de Oca, Alejandra Perez-Montes
Pardina, Eva
Genua, Idoia
Rojo-Lopez, Marina I.
Julian, Maria Teresa
Alonso, Nuria
Julve, Josep
Mauricio, Didac
FRONTIERS IN ENDOCRINOLOGY, 2024, 15
[27] A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis
Shah, Neha
Sanyal, Arun J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2025, 120 (01): : 75 - 82
[28] Macrophage phenotype is affected by longitudinal treatment with Zalfermin in a model of metabolic dysfunction-associated steatohepatitis
Kapel, Benedicte
Hancz, Dora
Medina, Cesar
Dermit, Maria
Jensen, Lise Flyger Walther
Veidal, Sanne Skovgard
Norlin, Jenny Egecioglu
Oldenburger, Anouk
Andersen, Birgitte
Pfister, Dominik
JOURNAL OF HEPATOLOGY, 2024, 80 : S574 - S575
[29] Spectroscopy of blood plasma has the potential to differentiate metabolic dysfunction-associated steatohepatitis from steatosis
Novakova, Barbora
Vrtelka, Ondrej
Kralova, Katerina
Zizalova, Katerina
Smid, Vaclav
Dvorak, Karel
Petrtyl, Jaromir
Vitek, Libor
Lenicek, Martin
Setnicka, Vladimir
Bruha, Radan
JOURNAL OF HEPATOLOGY, 2024, 80 : S539 - S540
[30] Hepatocellular RECK as a Critical Regulator of Metabolic Dysfunction-associated Steatohepatitis Development
Dashek, Ryan J.
Cunningham, Rory P.
Taylor, Christopher L.
Alessi, Isabella
Diaz, Connor
Meers, Grace M.
Wheeler, Andrew A.
Ibdah, Jamal A.
Parks, Elizabeth J.
Yoshida, Tadashi
Chandrasekar, Bysani
Rector, R. Scott
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 2024, 18 (03):

← 1 2 3 4 5 →